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Bridgehead-Methyl Analog of SC-53116 as a 5-HT4 Agonist 
Daniel P. Becker*, Daniel L. Flynn, and Clara I. Villamil 
Department of Medicinal Chemistry, Pfizer Research & Development, 4901 Searle Parkway, Skokie, IL 60077 
Pyrrolizidine (±)-2, the bridgehead-methyl analog of SC-53116, was prepared and evaluated for 5-HT4 
agonism activity in the rat tunica muscularis (TMM) mucosae assay.  Compound (±)-2 has an EC50 of 449 nM 
in the TMM assay, as compared to 23 nM for SC-53116, and 66 nM for the racemate of SC-53116. 
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Abstract—Pyrrolizidine benzamide (±)-2, the bridgehead-methyl analog of SC-53116, was 
prepared and evaluated for 5-HT4 agonism activity in the rat tunica muscularis (TMM) 
mucosae assay.  Compound (±)-2 has an EC50 of 449 nM in the TMM assay, as compared to 
23 nM for SC-53116, and 66 nM for the racemate of SC-53116. 
 
We have previously reported our discovery of SC-53116, which was the first selective 
agonist at the 5-HT4 receptor.1  SC-53116 has an ED50 of 23 nM in the tunica muscularis 
mucosae assay of Craig and Clarke,2 and is selective versus other monoamine receptors with 
a Ki of 152 nM at the 5-HT3 receptor and Ki’s of >10,000 nM at the 5-HT1, 5-HT2, D1, D 2, 
α1, α2 and β-receptors.  The 5-HT4 receptor was discovered by Clark2 and Bockaert3 in the 
brain and gut, respectively, and is expressed in a wide variety of tissues including brain, 
heart, bladder, gut and kidney.4  Selective ligands for the receptor show promise in the 
treatment of diseases including the irritable bowel syndrome, atrial arrhythmia, urinary 
incontinence, and gastrointestinal motility disorders.  An excellent review of the 5-HT4 
receptor and key ligands was recently published.5 
 
We have been interested in pursuing 5-HT4 agonists as gastrointestinal prokinetic agents.  
Our efforts in this area6 have also prompted us to develop several azatricyclic benzamides7 
that are potent 5-HT4 agonists and 5-HT3 antagonists, particularly SC-52491,8 in addition to 
the pyrrolizidine SC-53116. 
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SC-53116 was a clinical candidate but was halted when it was observed to be positive in the 
Ames assay when tested with S9 activation.9  We hypothesized that this toxicity was due to 
oxidation of the pyrrolizidine moiety to the bicyclic iminium ion 1, which can then function 
as an alkylating agent.  To avoid this liability, we targeted the bridgehead-methyl SC-53116 
analog (±)-2, as the methyl group would block metabolism to the iminium species.  We 
targeted the racemate initially to test the concept and ensure that sufficient potency is 
maintained with the additional methyl group. 
 
We employed general methodology reported by Meyers10 for introduction of the requisite 
quaternary carbon at the pyrrolizidinone bridgehead position.  As outlined in Scheme 1, 
ketoester 3 was heated under reflux with ethanolamine to afford (±)-411 in 53% yield.  The 
bicyclic lactam (±)-4 was treated with t-butyldimethylsilyl methyl acetate ketal12 in 2M 
lithium perchlorate ether13 to afford lactam (±)-5 in 30% yield.  Attempts with titanium 
tetrachloride in methylene chloride also afforded (±)-5 but in lower yield.  The primary 
alcohol of (±)-5 was converted to the tosylate in 86% yield by treating with tosyl chloride in 
pyridine.  Treatment of the tosylate with sodium iodide under Finkelstein conditions 
afforded the primary iodide (±)-6.   
 
Scheme 1:  Synthesis of (±)-2 
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A variety of bases were employed to effect closure of (±)-6, with potassium 
hexamethyldisilazide giving the best yield of (±)-7 and (±)-8 in a combined 70% yield.  The 
exo and endo methyl esters were isolated in a 1:2 ratio, with the endo (±)-8 as the main 
component, as determined by NOE.14  Reduction with lithium aluminum hydride gave a 
mixture of alcohols (±)-9 and (±)-10, and this mixture was converted directly to the 
phthalimides under Mitsunobu conditions, allowing chromatographic isolation of the 
requisite exo isomer (±)-11 in 24% yield.  Deprotection of (±)-11 with hydrazine gave the 
free amine in quantitative yield which was coupled directly with 5-acetamido-4-chloro-2-
methoxybenzoic acid utilizing carbonyl diimidazole to afford the desired benzamide.  The 
acetamide was removed with potassium hydroxide in ethanol under reflux to afford the 
desired benzamide isomer (±)-2 in 66% yield. 
 
Thus (±)-2, the bridgehead-methyl analog of SC-53116, was tested for agonist activity at the 
5-HT4 receptor in the rat tunica muscularis mucosae assay.  The potency for the compound 
was good, at 449 nM (± 185).  However, this was approximately 7X less potent than SC-
49518, the racemate of SC-53116, which has an EC50 of 66 nM ±11 nM.  Due to the loss of 
potency, the bridgehead methyl analog (±)-2 was not pursued further.  The azatricycle 
benzamide compounds that we developed7,8 are potent, efficacious, and safe, so we turned 
our attention to those molecules.  Specifically, SC-52491 was negative in the Ames assay at 
the highest concentrations tested, either with or without S9 activation.15 
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